Medical Oncology Department, Hospital Clínico Universitario San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain.
Medical Oncology Department, Hospital Clínico Universitario San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain.
Crit Rev Oncol Hematol. 2022 Jan;169:103569. doi: 10.1016/j.critrevonc.2021.103569. Epub 2021 Dec 7.
Immune-checkpoint inhibitors (ICIs) have shown to improve survival in the first- and second-line settings of recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN). In the past two years more than a dozen neoadjuvant IO studies have been reported in SCCHN, demonstrating the feasibility of one or a few doses of single agent or combination ICIs. This approach seems safe with no surgical delays due to toxicity in most of the studies with no new safety signals. Efficacy in terms of pathologic response appears promising both with single-agent ICIs and especially with chemo-IO combinations. The scientific rationale and current clinical evidence of neoadjuvant IO trials in SCCHN will be reviewed, including currently debated aspects such as the methodology for radiological and pathological evaluation as well as types and criteria for biomarker use in this setting. Finally, the future perspective of neoadjuvant IO in SCCHN will be approached.
免疫检查点抑制剂 (ICIs) 已被证明可改善复发性/转移性头颈部鳞状细胞癌 (SCCHN) 的一线和二线治疗中的生存情况。在过去的两年中，已经报道了十多项 SCCHN 的新辅助 IO 研究，证明了单药或联合使用一种或几种剂量的 ICIs 的可行性。在大多数研究中，由于毒性，没有因毒性而导致手术延迟，而且没有新的安全信号，这种方法似乎是安全的。在单药 ICIs 和特别是化疗联合 IO 方面，在病理反应方面的疗效似乎很有前景。本文将回顾 SCCHN 新辅助 IO 试验的科学依据和临床证据，包括目前存在争议的方面，如影像学和病理学评估的方法以及在该环境中使用生物标志物的类型和标准。最后，还将探讨 SCCHN 新辅助 IO 的未来前景。
